{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:35:28Z","timestamp":1772148928844,"version":"3.50.1"},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,6,1]]},"DOI":"10.2169\/internalmedicine.0599-22","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T22:15:43Z","timestamp":1685571343000},"page":"1647-1652","source":"Crossref","is-referenced-by-count":7,"title":["Aortitis Associated with Prophylactic Short-acting Granulocyte Colony-stimulating Factor Administration: A Case Report and Review of the Literature"],"prefix":"10.2169","volume":"62","author":[{"given":"Yasutaka","family":"Masuda","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumi","family":"Nakazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudai","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Masamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"},{"name":"Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414-1422, 1988.","DOI":"10.1056\/NEJM198806023182202"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24: 2475-2484, 2013.","DOI":"10.1093\/annonc\/mdt226"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin&apos;s lymphoma. Leuk Lymphoma 44: 1503-1508, 2003.","DOI":"10.1080\/1042819031000103953"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. D&apos;Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev 22: 280-290, 2008.","DOI":"10.1016\/j.tmrv.2008.05.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lardieri A, McCulley L, Christopher Jones S, Woronow D. Granulocyte colony-stimulating factors and aortitis: a rare adverse event. Am J Hematol 93: E333-E336, 2018.","DOI":"10.1002\/ajh.25220"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Ito Y, Noda K, Aiba K, Yano S, Fujii T. [Diffuse large B-cell lymphoma complicated with drug-induced vasculitis during administration of pegfilgrastim]. Rinsho Ketsueki 58: 2238-2242, 2017 (in Japanese).","DOI":"10.11406\/rinketsu.58.2238"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sasaki K, Miyauchi M, Ogura M, et al. Arteritis after administration of granulocyte colony-stimulating factor: a case series. Int J Hematol 110: 370-374, 2019.","DOI":"10.1007\/s12185-019-02662-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sasaki K, Matsuda K, Miyauchi M, et al. A retrospective analysis on arteritis after administration of granulocyte colony-stimulating factor. Ann Hematol 100: 1341-1343, 2021.","DOI":"10.1007\/s00277-021-04453-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yamamoto S, Waki D, Maeda T. Granulocyte-colony stimulating factor-induced vasculitis successfully treated with short-term corticosteroid therapy: a case report. Cureus 13: e20563, 2021.","DOI":"10.7759\/cureus.20563"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Oshima Y, Takahashi S, Tani K, Tojo A. Granulocyte colony-stimulating factor-associated aortitis in the Japanese adverse drug event report database. Cytokine 119: 47-51, 2019.","DOI":"10.1016\/j.cyto.2019.02.013"},{"key":"11","unstructured":"11. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin&apos;s lymphomas. Cancer Treat Rep 61: 1023-1027, 1977."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ueda K, Nannya Y, Asai T, et al. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed\/refractory B-cell lymphoma. J Chemother 22: 54-57, 2010.","DOI":"10.1179\/joc.2010.22.1.54"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32: 3059-3068, 2014.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 28: 1436-1447, 2017.","DOI":"10.1093\/annonc\/mdx097"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Muzzana M, Pedrazzoli P, Lasagna A. G-CSF and G-CSF-related vasculitis: a systematic review of the literature and intriguing future research perspectives. Future Oncol 17: 4619-4634, 2021.","DOI":"10.2217\/fon-2021-0701"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yamamoto K, Tamura N, Oka K, et al. Large-vessel vasculitis induced by granulocyte colony-stimulating factor administration after chemotherapy. Mod Rheumatol Case Rep 5: 322-326, 2021.","DOI":"10.1080\/24725625.2020.1857022"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol 55: 481-486, 2002.","DOI":"10.1136\/jcp.55.7.481"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kermani TA. Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease? Int J Rheum Dis 22: 41-48, 2019.","DOI":"10.1111\/1756-185X.13288"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Restrepo CS, Ocazionez D, Suri R, Vargas D. Aortitis: imaging spectrum of the infectious and inflammatory conditions of the aorta. Radiographics 31: 435-451, 2011.","DOI":"10.1148\/rg.312105069"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sato Y, Kaji S, Ueda H, Tomii K. Thoracic aortitis and aortic dissection following pegfilgrastim administration. Eur J Cardiothorac Surg 52: 993-994, 2017.","DOI":"10.1093\/ejcts\/ezx165"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Miller EB, Grosu R, Landau Z. Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF). Clin Rheumatol 35: 1655-1657, 2016.","DOI":"10.1007\/s10067-016-3253-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Molineux G, Kinstler O, Briddell B, et al. A new form of Filgrastim with sustained duration <i>in vivo<\/i> and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27: 1724-1734, 1999.","DOI":"10.1016\/S0301-472X(99)00112-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD\/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18: 2522-2528, 2000.","DOI":"10.1200\/JCO.2000.18.13.2522"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21: 514-519, 2003.","DOI":"10.1200\/JCO.2003.03.040"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. Kubo K, Miyazaki Y, Murayama T, et al. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE (R) chemotherapy for malignant lymphoma. Br J Haematol 174: 563-570, 2016.","DOI":"10.1111\/bjh.14088"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27. Mohseni M, Arab-Zozani M, Ahmadi A, Salimi B, Sari AA. Meta-analysis of pegfilgrastim over filgrastim in the treatment of chemotherapy-induced neutropenia. Ann Cancer Res Ther 28: 71-80, 2020.","DOI":"10.4993\/acrt.28.71"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Cornes P, Gascon P, Chan S, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther 35: 1816-1829, 2018.","DOI":"10.1007\/s12325-018-0798-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29. Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol 14: 302-314, 2014.","DOI":"10.1038\/nri3660"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433-2453, 2006.","DOI":"10.1016\/j.ejca.2006.05.002"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33: 3199-3212, 2015.","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32. Koyama Y, Adachi K, Yagi M, et al. Successful treatment of G-CSF-related aortitis with prednisolone during preoperative chemotherapy for breast cancer: a case report. Surg Case Rep 7: 23, 2021.","DOI":"10.1186\/s40792-021-01111-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33. Lee SY, Kim EK, Kim JY, et al. The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer. Sci Rep 10: 18647, 2020.","DOI":"10.1038\/s41598-020-75620-6"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/11\/62_0599-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:32:30Z","timestamp":1715315550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/11\/62_0599-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0599-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"article-number":"0599-22"}}